El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Maravai LifeSciences Holdings Inc (Class A)
Abierto
SectorSalud
3.15 3.28
Resumen
Variación precio
24h
Mínimo
3.05
Máximo
3.25
Ingresos | -15M -40M |
|---|---|
Ventas | 8.2M 50M |
Margen de beneficio | -80.43 |
Empleados | 435 |
EBITDA | -19M -42M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +29.87% upside |
Próximas Ganancias | 11 may 2026 |
|---|
Capitalización de Mercado | 214M 1.3B |
|---|---|
Apertura anterior | -0.13 |
Cierre anterior | 3.15 |
Noticias sobre sentimiento de mercado
By Acuity
50%
50%
150 / 351 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Bullish Evidence
Maravai LifeSciences Holdings Inc (Class A) Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Maravai LifeSciences Holdings Inc (Class A) Esperado
Precio Objetivo
By TipRanks
29.87% repunte
Estimación a 12 meses
Media 4 USD 29.87%
Máximo 5 USD
Mínimo 3 USD
De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Maravai LifeSciences Holdings Inc (Class A) Dist en los últimos 3 meses.
Sentimiento
By Acuity
150 / 351 Clasificación en Salud
Noticias sobre sentimiento de mercado
Neutral
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Maravai LifeSciences Holdings Inc (Class A)
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
Live chat